目的：比较布林佐胺-溴莫尼定（BB）（1％0.2％）与金标准拉坦前列素-噻吗洛尔（LT）（0.005％0.5％）治疗原发性开角型青光眼（POAG）和高眼压症（OHT）的疗效。方法：一项为期1年的前瞻性研究，从2022年5月到2023年5月，在一家三级眼科医院进行。参与者,40-60岁，基线眼压（IOP）>21mmHg，需要>30%的减少，已注册。A组（n=100）接受BB，B组(n=100)接受LT。在1个月时评估结果（IOP与基线的差异），3和6个月（平均昼夜变化）。结果：A组的平均年龄为55.5±4.5岁，B组的平均年龄为54.7±4.2岁。A组的平均眼压为18.7mmHg,而B组有17.6mmHg，差异无统计学意义(P=0.53)。两组均无显著昼夜变化(P=0.07)。A组88%的患者达到目标压力，B组92%略高。没有严重副作用的报道，B组(98%)的依从性高于A组(96%)。结论：虽然LT显示出略好和持续的眼压降低，差异无统计学意义。BB和LT在管理POAG和OHT方面均表现出可比的结果。
Purpose: To compare the efficacy of Brinzolamide-Brimonidine (BB) (1%+0.2%) with the gold standard Latanoprost-Timolol (LT) (0.005%+0.5%) in treating primary open-angle glaucoma (POAG) and ocular hypertension (OHT). Methods: A 1-year prospective study, spanning from May 2022 to May 2023, conducted at a tertiary eye-care hospital. Participants, aged 40-60, with a baseline intraocular pressure (IOP) >21 mm Hg, requiring a >30% reduction, were enrolled. Group A (n = 100) received BB, and Group B (n = 100) received LT. Outcomes were assessed at 1 month (IOP difference from baseline), 3 and 6 months (mean diurnal variations). Results: The mean age at presentation was 55.5 ± 4.5 years in Group A and 54.7 ± 4.2 years in Group B. At 1 month, Group A exhibited a mean IOP of 18.7 mm Hg, while Group B had 17.6 mm Hg, with no statistically significant difference (P = 0.53). No significant diurnal variation was observed in either group (P = 0.07). Target pressure was achieved in 88% of patients in Group A and slightly higher at 92% in Group B. Moreover, no serious side effects were reported, and compliance was higher in Group B (98%) compared to Group A (96%). Conclusion: Although LT showed slightly better and sustained IOP reduction, the difference was not statistically significant. Both BB and LT demonstrated comparable outcomes for managing POAG and OHT.
